Uforia 7-OH + 13-OH 600mg Tablets 15ct

Uforia 7-OH + 13-OH 600mg Tablets 15ct

Uforia 7-OH + 13-OH tablets combine two kratom‑derived alkaloids—7‑hydroxymitragynine (7OH) and 13‑hydroxymitragynine (13OH) — into standardized tablet formats designed for precise, consistent dosing and a more controlled user experience.​

40mg chewable tablets

• Each chewable tablet contains a combined 40mg of total alkaloids from 7OH and 13OH (full spec 7‑hydroxymitragynine + 13‑OH Corydallis Yanhusho).​
• Serving size is 1/4 tablet, allowing users to work with smaller portions and better gauge individual tolerance.​
• Chewable format is built for water‑free, on‑the‑go use, with a smoother mouthfeel than raw powder and no need for measuring or mixing.​
• Other tablet ingredients include microcrystalline cellulose, silicon dioxide, dicalcium phosphate, magnesium stearate, and food‑grade colorants.​

Standardized dual‑alkaloid formula

• Dual‑alkaloid profile (7OH + 13OH) is standardized so each tablet provides the same amount of total active alkaloids, supporting predictable handling and intake.​
• Focus on batch‑to‑batch consistency helps maintain accurate labeling and reliable alkaloid content across all tablets.​
• Because both 7OH and 13OH are potent compounds, the product emphasizes careful, fractioned dosing and awareness of individual response rather than frequent or high‑dose use.​

Swallowable 7‑Hydroxy tablet positioning

• Uforia also promotes its 7‑OH format as a “rapid release” tablet designed to be swallowed, targeting users who prefer a non‑chewable option with fast onset and a cleaner flavor profile versus typical chewables.​
• These tablets are positioned as a unique, premium 7‑hydroxy offering with in‑house extraction and full‑spectrum 7‑OH that includes minor alkaloids for a more “complete” kratom‑style profile.​

Brand & quality claims

• In‑house extraction: Uforia states that it extracts its own 7‑hydroxymitragynine to maintain control over purity and composition.​
• Accurate, honest dosing: Marketed as delivering exactly what is on the label with no “label inflation” or gimmicks.​
• Full‑spectrum 7‑hydroxy and dual‑alkaloid design are used as key differentiators from basic, single‑alkaloid 7‑OH tablets.​
• Rapid‑release tablets, premium tablet finish, and vibrant packaging are highlighted to support a top‑shelf, retail‑ready presentation.​

Safety, compliance & disclaimer

• Users are instructed to read the entire label before use and to handle the product responsibly, as safety, dosage, and long‑term impacts of concentrated 7OH/13OH are not fully established.​
• As with all kratom‑derived products, legality and regulations vary by location, so users are advised to confirm local compliance before purchase or use.​
• These statements have not been evaluated by the Food and Drug Administration, and the product is not intended to diagnose, treat, cure, or prevent any disease.​